Cipla Vice Chair Explores Lung Leadership Vision With Biosimilars Opportunities
Samina Hamied Also Discusses Industry’s Expectations From Indian Government
Executive vice chairperson of Cipla Samina Hamied talks to Generics Bulletin about the company’s intention to become global lung leaders on the back of biosimilars opportunities and its inhalation assets. As well as discussing Cipla’s three-year strategy, Hamied – who is also the vice president of IPA – discusses creating a favorable regulatory and policy landscape in India.
You may also be interested in...
Cipla signals more US momentum with headroom for albuterol market share expansion, promising prospects for generic Brovana and strong launch line-up in FY23, but analysts also keep close eye on regulatory pre-approval inspection timelines.
Viatris has voluntarily recalled one batch of its Semglee (insulin glargine) pre-filled pens due to the potential for the label to be missing on some pre-filled pens within a labelled carton. The company said that it will arrange for the return of all recalled products.
Amneal’s president and co-CEO, Chirag Patel, has shared the company’s long-term plan of becoming one of the top biosimilars players in the US. The company is set to launch three biosimilars this year, while building its manufacturing capabilities and looking for opportunities and partnerships.